Background Psoriasiform and eczematous eruptions are the most common dermatological adverse reactions linked to anti-tumour necrosis factor (TNF)-a therapy. Yet, a detailed characterization of their immune phenotype is lacking. Objectives To characterize anti-TNF-a-induced inflammatory skin lesions at a histopathological, cellular and molecular level, compared with psoriasis, eczema (atopic dermatitis) and healthy control skin. Methods Histopathological evaluation, gene expression (quantitative real-time polymerase chain reaction) and computer-assisted immunohistological studies (TissueFAXS) were performed on 19 skin biopsies from patients with inflammatory bowel disease (n = 17) and rheumatoid arthritis (n = 2) with new-onset inflammatory skin lesions during anti-TNF-a-therapy. Results Although most biopsies showed a psoriasiform and/or spongiotic (eczematous) histopathological architecture, these lesions were inconsistent with either psoriasis or eczema on a molecular level using an established chemokine (C-C motif) ligand 27/inducible nitric oxide synthase classifier. Despite some differences in immune skewing depending on the specific histopathological reaction pattern, all anti-TNF-a-induced lesions showed strong interferon (IFN)-c activation, at higher levels than in psoriasis or eczema. IFN-c was most likely produced by CD3/CD4/Tbet-positive T helper 1 lymphocytes. Conclusions New-onset anti-TNF-a-induced eruptions previously classified as psoriasis or spongiotic dermatitis (eczema) exhibit a molecular profile that is different from either of these disorders.
What is the translational message?
• The results might help to guide future treatment strategies for chronic inflammatory diseases preventing these side-effects in the skin.
Anti-tumour necrosis factor (TNF)-a antibodies are efficacious therapeutics for chronic inflammatory diseases such as Crohn disease, ulcerative colitis, rheumatoid arthritis and psoriasis, with an overall favourable safety profile. 1 Psoriasiform and eczematous skin eruptions have turned out to be the most frequent inflammatory skin complications of TNF-a-blocker treatment, 2-6 with a cumulative incidence of 28Á9% at 10 years, leading to anti-TNF-a discontinuation in 18Á6% of patients. 5 After switching to a different TNF-a-blocker, a recurrence rate of 57% was observed, suggesting a class effect.
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While TNF-a-blockers increase blood eosinophil levels 7 and worsen pre-existing eczema, 8, 9 the advent of psoriasiform lesions came as a surprise, 10 as TNF-a-blockers are generally a well-established anti-psoriatic treatment modality. 11 Currently, psoriasiform lesions are classified as 'classic' psoriasiform, inverse, palmoplantar, palmoplantar pustular, guttate and scalp psoriasiform lesions. 12 Eczematous lesions, which are histologically characterized by a spongiotic inflammatory reaction (spongiotic dermatitis), have not been further classified. 8 Other inflammatory cutaneous side-effects include lupus-like disorders, vasculitis and granulomatous and lichenoid reactions, but these appear at much lower frequencies. 13 A disturbed T helper (Th) 1/Th2 balance has been postulated as the basis for eczematous lesions, 14 suggesting TNF-a as an important Th1 component that can suppress Th2 responses, 8 with Th2 cytokines driving the formation of eczema. 15 However, deeper mechanistic insights are lacking.
In the context of psoriasiform lesions, which have been shown to be rich in Th1 and Th17 immune cells and to respond to the interleukin (IL)-12/IL-23p40 blocker ustekinumab, 4 there is some evidence that TNF-a-blockade can lead to unopposed interferon (IFN)-a production by plasmacytoid dendritic cells (pDCs), 3, 10, [16] [17] [18] which have also been suggested as key drivers in the development of conventional psoriasis. [19] [20] [21] However, sifalimumab, an IFN-a-blocker, failed to elicit effects on psoriasis in a clinical trial, 22 challenging the central role of IFN-a in this disease, at least in fully established lesions. Despite the fact that several studies have described potential driver cytokines in anti-TNF-induced skin lesions, 3, 4, 17, 18, 23 a comparative, broad immunological characterization of anti-TNF-a-induced inflammatory skin lesions is still lacking. We thus decided to assess them comprehensively at a histopathological, molecular and cellular level. We found that anti-TNF-a-induced 'psoriasiform' and 'eczematous/spongiotic' skin lesions lack some key immune features of psoriasis and eczema, with strong Th1-and IFN-a-associated inflammation.
Patients and methods

Patient characteristics and skin samples
Nineteen patients on anti-TNF-a-treatment were referred to our outpatient clinic because of new-onset scaly erythematous skin lesions (Table 1) . A total of 17 (90%) were being treated for inflammatory bowel disease (15 with Crohn disease, two with ulcerative colitis), and two for rheumatoid arthritis. They were being treated with adalimumab (n = 14), infliximab (n = 4) or golimumab (n = 1). The mean AE SD age of participants was 40Á4 AE 13Á9 years, and the median duration of therapy was 24 months (range 7-105 months). Of the 19 patients, 17 (90%) were negative for antinuclear antibodies. There was neither a prior history of psoriasis nor of eczema (or associated atopy) in any individual, and no one reported injection-site reactions. Punch biopsies (4 mm) were obtained from clearly inflamed skin without prior topical treatment. Biopsies from patients with classic plaque-type psoriasis (n = 6), atopic eczema (atopic dermatitis, n = 9) and from healthy controls (n = 5) served as comparators. Biopsies were taken under guidance from an institutional review board-approved protocol (Ethics Committee of the Medical University of Vienna, Austria; approval number: 071/2005) according to the Declaration of Helsinki. All participants gave written informed consent prior to inclusion.
Quantitative real-time polymerase chain reaction RNA was isolated with TRI Reagent â (Sigma-Aldrich Co., St Louis, MO, U.S.A.) and transcribed to cDNA as previously described. 24 mRNA levels were normalized to the established housekeeping gene human b 2 -microglobulin (B2M), 25 and results depicted as log 2 -fold increase over healthy control skin. Primers and probes for TaqMan qRT-PCR assays (Table S1 ; see Supporting Information) were used from TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, U.S.A.).
Skin samples and histopathological evaluation
Formalin-fixed skin specimens were embedded in paraffin, processed, stained with haematoxylin and eosin (H&E) and analysed by light microscopy. A board-certified dermatopathologist analysed all samples in a blinded fashion. Assessment of histopathological features was performed in a semiquantitative fashion (Table 2) , and graded according to a previously described histopathological psoriasis scoring system (HPSS).
26,27
Multicolour immunofluorescence stainings and semiautomated analysis
Multicolour immunofluorescence stainings were performed on frozen sections, 28, 29 and analysed using Strataquest V64
(TissueGnostics GmbH, Vienna, Austria) in a semiautomated fashion (TissueFAXS; TissueGnostics GmbH), as previously established. 28 Briefly, a first set of analysis layers was applied to differentiate automatically between epidermal, upper and lower dermal areas (based on cell density/4 0 ,6-diamidino-2-phenylindole staining and a background of immunofluorescence channels). The detected regions were manually controlled, and, if necessary, corrected by adding/substracting areas. Natural killer (NK) cells and T-cell subsets were gated based on mean immunofluorescence intensity of the respective channels, and cut-offs were adapted according to isotype controls.
Statistical analysis
B2M normalized mRNA expression values were log 2 -transformed prior to analysis. All analyses were carried out in R (R Foundation, Vienna, Austria) and its available packages. Differences in expression values (in log 2 -scale) and cell counts were assessed using a linear mixed-effects model. Once the model was fitted (using the lme function), least-square means were obtained, and group comparisons were assessed by a twotailed t-test using contrasts (using the functions lsmean and contrast in the R package lsmeans). Condition (atopic dermatitis, psoriasis, anti-TNF-induced lesion) was considered as a fixed factor and participant ID as a random effect with 'lsmeans', least-square means and standard error of the mean for each condition estimated. The function 'contrast' was used to estimate and contrast the differences between means (individual null hypothesis). The overall null hypothesis was tested by the 'test' function, which executes a Fisher test. Statistical significance was assigned at P ≤ 0Á05. False discovery rates were calculated using the Benjamini-Hochberg procedure (Table S2 ; see Supporting Information).
Results
Clinical appearance and histopathological classification
We analysed 19 biopsies from patients with new-onset anti-TNF-a-related inflammatory skin eruptions (Table 1) . Affected regions included the trunk, extremities, palms, soles and the scalp. All scalp lesions were clinically accompanied by visible hair loss (alopecia). H&E-stained specimens were assessed by a dermatopathologist for histological reaction patterns. Results were grouped according to an established scoring system, HPSS, 26, 27 and compared with findings suggestive of drug eruption (Table 2) . Seven lesions showed reaction patterns that were mainly consistent with psoriasis, reflected by a HPSS > 13, 26, 27 and were thus classified as 'psoriasiform' (n = 7). Seven samples yielded low HPSS scores, and displayed histopathological features most consistent with spongiotic dermatitis (eczema). Three samplesall from the scalp -exhibited a mixed histopathological reaction pattern with both psoriasiform and spongiotic features, consistent with an intermediate HPSS score. Two remaining biopsies yielded a low HPSS score and showed a dense lichenoid lymphocytic cell infiltrate at the dermoepidermal junction, and were thus classified as lichenoid. Representative images of these four reaction patterns are shown in Figure 1 .
On a molecular level, psoriasiform and spongiotic/ eczematous anti-tumour necrosis factor-induced skin lesions are distinct from both psoriasis and eczema
As anti-TNF-induced psoriasiform and spongiotic/eczematous skin lesions were histopathologically consistent with psoriasis and eczema (spongiotic dermatitis), respectively, we assessed these biopsies with an established molecular disease classifier. 30 This classifier consists of the two inflammatory mediators, nitric oxide synthase 2 [NOS2 or inducible nitric oxide synthase (iNOS)] and chemokine (C-C motif) ligand (CCL) 27, with high NOS2 and low CCL27 mRNA levels being characteristic of psoriasis, and low NOS2 and high CCL27 levels being characteristic of eczema. 30, 31 Surprisingly, neither psoriasiform nor spongiotic/eczematous anti-TNF-induced lesions showed a molecular pattern characteristic of classic psoriasis or eczema (Fig. 2a-d) . Similarly, neither scalp lesions (Fig. 2e, f (IL12RB2), and the chemokine (C-X-C motif) ligand (CXCL) 9/CXCL10/CXCL11 chemokine receptor chemokine (C-X-C motif) receptor 3 (CXCR3) (Figs 3a-c and S1c), which, in turn, is classically found on Th1 cells. Across all anti-TNF-a lesions, we also found levels of the innate immune markers IFN-a1 and the antimicrobial peptide lipocalin (LCN)-2, both involved in Th1 priming, 34, 35 to be higher than in psoriasis and eczema, but with lower levels in scalp samples than in psoriasiform or eczematous/spongiotic lesions (Figs 3a-c and S1c).
The strong interferon-c signature in anti-tumour necrosis factor-a lesions is consistent with increased numbers of T helper 1 cells, but not type 1 cytotoxic T cells or natural killer cells
To identify the potential cellular source(s) of the strong IFN-c signature in anti-TNF-a lesions, we quantified cells that classically produce this cytokine, namely NK cells, Th1 and type 1 cytotoxic T cells (Tc1), 36 using a semiautomated histology analysis of multicolour immunofluorescence staining. 28 In both and (e) and (f) scalp lesions are depicted as log 2 fold change (FCH) relative to healthy control skin, and compared with levels found in classic psoriasis and eczema (spongiotic dermatitis); data are normalized to b 2 -microglobulin (B2M) expression; 95% confidence interval boxplot and least-square mean AE standard error of the mean; *P ≤ 0Á05, **P ≤ 0Á01, ***P ≤ 0Á001.
Fig 3.
Real-time polymerase chain reaction heat maps of mRNA expression levels. mRNA levels were normalized to b 2 -microglobulin, and depicted as colour-coded mean log 2 fold changes over healthy control skin. Red denotes increases, and blue denotes decreases relative to healthy control samples. Heat maps were assembled using nonhierarchical clustering. Samples of conventional psoriasis (plaque-type psoriasis, n = 6) and eczema (atopic dermatitis, n = 9) were used as comparators for each group of anti-tumour necrosis factor (TNF)-induced inflammatory skin lesions, which were stratified for histological criteria of (a) psoriasiform (n = 7), (b) spongiotic (n = 7) and (c) scalp lesions (n = 3). Large frames denote clusters of maximal expression levels in psoriasis (blue), eczema (pink), and anti-TNF-induced lesions (black), respectively. Grey solid boxes mark molecules that were maximally upregulated in all groups of anti-TNF-induced lesions.
psoriasiform and spongiotic/eczematous lesions we found only very low numbers of NK cells, even lower than in healthy control skin (Fig. 4a) . By contrast, we identified a prominent infiltrate of T cells in anti-TNF-a lesions (Fig. 4b ). Among these, only Th1 cells (Fig. 4c) , but not Tc1 cells (Fig. 4d) were significantly elevated compared with healthy control tissues. Scalp and lichenoid lesions were not assessed because of the small sample size.
Distinct cytokine pattern between psoriasiform, eczematous and scalp lesions
Apart from Th1 activation that was consistently strong in all histological subtypes, anti-TNF-a-induced skin lesions showed some changes specific to the respective histological subtype (Fig. 5) . Lichenoid eruptions were not assessed because of their limited sample size. Psoriasiform lesions showed normal levels of the skin barrier protein filaggrin, as opposed to lower levels in eczematous and scalp lesions (Fig. 5a ). Both psoriasiform and eczematous lesions showed increases in the proinflammatory mediators IL-36A, IL-36G, IL-19, and IL-20, in addition to the IFN-a marker Mx1, whereas scalp lesions lacked upregulation of these mediators (Fig. 5b-f ). In contrast, only eczematous lesions showed upregulation of Th2-associated mediators such as IL-13, IL-5 and CCL26 (Fig. 5g-i) , and showed the highest levels of the Th22-cytokine IL-22, not only compared with other anti-TNF-a lesions (Fig. 5j) , but also compared with conventional psoriasis and eczema (Figs 3a-c and S1c). We assessed numbers of leucocytes in healthy controls (n = 10), psoriasis (n = 15), eczema (n = 13) and anti-tumour necrosis factor (TNF)-induced skin lesions (psoriasiform n = 5, eczematous n = 5), using markers for (a) natural killer (NK) cells and (b) T cells. T cells were further divided into (c) T helper (Th1) 1 cells and (d) type 1 cytotoxic T (Tc1) cells, as assessed by the type 1 transcription factor Tbet; 95% confidence interval boxplot and least-square mean AE standard error of the mean of cell counts per mm epidermis; *P ≤ 0Á05, **P ≤ 0Á01, ***P ≤ 0Á001.
Discussion
By characterizing anti-TNF-induced inflammatory skin eruptions, we could stratify them into four histopathological reaction patterns, with the highest numbers of psoriasiform and eczematous lesions. However, we found that these eruptions are distinct from conventional psoriasis and eczema, using a molecular disease classifier. 30, 37 Also, biopsies from so-called inflammatory or psoriasiform alopecia of the scalp, 12 which showed histopathological characteristics of both psoriasis and spongiotic dermatitis, did not meet molecular criteria of either disease. The original classifier used a ratio built of NOS2 and CCL27; however, we decided to depict individual cohorts (fold change over healthy control), in line with the other markers investigated.
Despite their different histological patterns, all anti-TNF-ainduced lesions were unified by high IFN-c responses that were higher than in conventional eczema or psoriasis. This immune axis was also strongly activated in two lichenoid samples. The small sample size precluded their further characterization but they at least served as a positive control for IFNc-dependent inflammation. 38 The fact that among potential IFN-c producing cell types, Th1 cells, but not Tc1 or NK cells, were most abundant, suggests the Th1 adaptive immune axis as a likely contributor to skin inflammation in these patients. Mechanistically, the strong Th1 response might be fuelled by increases in IFN-a, a type I IFN, consistent with published reports.
3 TNF-a is thought to be an inhibitor of pDC development and IFN-a production. 18 Consequently, TNF-blockade might disturb a pre-existing ; 95% confidence interval boxplot and least-square mean AE standard error of the mean of log 2 fold change in mRNA/B2M relative to healthy control skin; *P ≤ 0Á05, **P ≤ 0Á01, ***P ≤ 0Á001. FCH, fold change; B2M, b 2 -microglobulin.
cytokine balance between TNF-a and IFN-a in affected skin, favouring pDC-derived IFN-a secretion. 41 a receptor typically found on Th1 cells, which was also increased in all our samples, in line with previous reports in psoriasiform lesions. 3 In the peripheral blood, it has been
shown that TNF-blockers increase expression of CXCR3 on circulating T cells in patients with rheumatoid arthritis, possibly promoting skin homing of these cells. 42 Furthermore, increases in IL12RB2, a receptor subunit of the pivotal Th1-polarizing cytokine IL-12, might be another component of an amplification loop of this type 1 immune response fuelling skin inflammation during TNF-blockade.
Although the role of IFN-a, especially in autoimmune diseases, has traditionally been linked to Th1 responses, 43 it has now also been associated with priming and expansion of Th17 cells. 44 Albeit most strongly increased in psoriasis, some Th17-associated mediators (IL-17A, S100A8, S100A9, S100A12 and PI3) were also upregulated in all anti-TNF-ainduced lesions, suggesting a contribution of the Th17 immune axis in the formation of these lesions. Importantly, a rare coding variant of the IL23R gene, which has previously been associated with increases in Th17 cytokine production, 45 has been described in patients with severe psoriasiform and/ or anti-TNF-induced alopecia. 4 It is well established that antimicrobial peptides such as human beta-defensin 2 (encoded by the DEFB4 gene) or cathelicidin antimicrobial peptide (CAMP)/LL37 are upregulated in psoriasis compared with atopic eczema, 46 and they are thought to be critically involved in the pathogenesis of psoriasis via triggering autoinflammatory immune responses in dendritic cells. 21 In psoriasiform and spongiotic/eczematous anti-TNF-a lesions, CAMP/LL37 was upregulated at even higher levels than in psoriasis, mandating further investigation as to their proinflammatory contribution in these lesions. Despite this consistent upregulation of Th1-associated mediators across all subsets of anti-TNF-induced lesions, we also found several important differences between them. In scalp lesions, the IFN-a/Mx1 component was missing. So far, 'psoriasiform' alopecia has been recognized as part of a spectrum of anti-TNF-a-induced psoriasiform lesions, i.e. psoriasis of the scalp with patchy hair loss. 4, 47 However, scalp lesions did not only lack IFN-a responses, they also showed low IL-19 and IL-20 levels, two cytokines classically upregulated in psoriasis, 33 that were also present in our psoriasiform and eczematous lesions. Moreover, scalp lesions lacked IL-36A and IL-36G, two IL-1-family cytokines classically upregulated in psoriasis. 48, 49 It has been suggested that in anti-TNF-ainduced psoriasiform skin lesions, IL-36G sustains a proinflammatory self-amplifying loop with IL-17C, 23 and that and IL-36G might have a proinflammatory role in psoriasiform and eczematous lesions outside the scalp, they are likely less relevant to anti-TNF-induced scalp lesions. Overall, and despite a small sample size, our data consistently demonstrate clear differences distinguishing anti-TNF-ainduced scalp lesions not only from spongiotic/eczematous lesions, but also from psoriasiform lesions in body regions other than the scalp. We are also confident that the lower abundance of these cytokines in scalp biopsies was not because of the selection of only mildly inflamed lesions, as the same samples showed strong increases in S100A proteins, IL-17A or PI3, that were present at even higher levels than in for example eczema samples.
Lesions with a spongiotic/eczematous histopathological reaction pattern differed from psoriasiform and from scalp lesions by increases in Th2-associated cytokines (IL-13/ CCL26/IL-5), potentially explaining the eczematous histopathological features of this anti-TNF-a subgroup, as these mediators are implicated as key pathogenic mediators in eczema. 52 Spongiotic/eczematous anti-TNF-a lesions also
showed the highest levels of IL-22 among all groups, including psoriasis and eczema. This Th17/Th22 cytokine has been demonstrated to promote epidermal hyperplasia and to inhibit epidermal differentiation, 53 which makes IL-22 a potential trigger of the pathogenic disease phenotype in spongiotic (eczematous) anti-TNF-a lesions. Psoriasiform lesions, in turn, lacked downregulation of filaggrin, which is considered an important contributor to the skin barrier and has been implicated as being central to the development of eczema.
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Our patients, who mostly had inflammatory bowel disease, all developed skin lesions for the first time during TNF-ablockade, limiting the results of this study to this specific patient group. In patients with pre-existing eczema and psoriasis, this can also flare-up with anti-TNF-a treatment, 8, [55] [56] [57] but it remains to be determined whether their immune profile is similar to that of new-onset lesions. Another limitation of this pilot study is the small sample size, and results need to be confirmed in larger patient cohorts.
In sum, we demonstrate that new-onset psoriasiform, eczematous and scalp anti-TNF-induced skin lesions are distinct immunological entities with characteristic Th1/IFN-c/ IFN-a-associated inflammation and major differences from both conventional psoriasis and eczema.
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